产品说明书
Mepenzolate bromide
 |
同义名 : | Mepenzolate (bromide);NSC 4358;mepenzolic acid;mepenzolate iodide;Cantilon;Cantilaque;Gastropidil;Cantil |
| CAS号 : | 76-90-4 | |
| 货号 : | A288808 | |
| 分子式 : | C21H26BrNO3 | |
| 纯度 : | 98% | |
| 分子量 : | 420.34 | |
| MDL号 : | MFCD00079450 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 250 mg/mL(594.76 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 10 mg/mL(23.79 mM)，配合低频超声，并水浴加热至45℃助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Mepenzolate bromide (MP), an antagonist for human muscarinic M3 receptor (hM3R), has both anti-inflammatory and short-acting bronchodilatory activities[3]. Mepenzolate bromide, used to treat gastrointestinal disorders in clinical settings, also displayed beneficial effects in chronic obstructive pulmonary disease and pulmonary fibrosis of a mouse model by inhibiting inflammatory responses and reducing oxidative stress[4]. Apart from suppressing elastase-induced pulmonary inflammatory responses and the production of superoxide anions, mepenzolate bromide reduces the level of cigarette smoke-induced airspace enlargement and respiratory dysfunction. Mpenzolate bromide may be an effective therapeutic for the treatment of COPD (chronic obstructive pulmonary disease) due to its anti-inflammatory and bronchodilatory activities[5]. The intratracheal administration of mepenzolate reduced bleomycin-induced pulmonary fibrosis and lung dysfunction in mice[6]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.38mL 0.48mL 0.24mL |
11.90mL 2.38mL 1.19mL |
23.79mL 4.76mL 2.38mL |
| 参考文献 |
|---|